Pharmaceutical company Pharmsynthez the resident of the cluster of biomedical technologies of the Skolkovo Foundation Fusion Pharma signed a license agreement on the commercialization of the innovative drug for leukemia PF-114, says the press service of the group of companies.
Pharmsynthez intends to take over the clinical research of the third phase and realize state registration and commercialization of this drug in the EAEU countries. Fusion Pharma grants Pharmsynthez exclusive rights to manufacture and sell drug candidate PF-114. Other terms of the transaction are not disclosed by the parties.
«It is very important that the development of the drug PF-114 for the treatment of chronic myeloid leukemia by Fusion Pharma has been recognized by an industrial partner – Pharmsynthez – and the signed license agreement will ensure, as a result of registration studies, patients’ access to new therapy», said Kirill Kayem, senior vice president for innovation at the Skolkovo Foundation.
Drug candidate PF-114 is a third-generation targeted drug developed by the Russian company Fusion Pharma. It is intended for the treatment of chronic myeloid leukemia (CML), which cannot be treated with drugs of the first and second generations. Based on the results of the first phase multicenter clinical research, the target group of patients selected a dose of PF-114 with an optimal efficacy-safety ratio, which is planned for further study as part of the third phase registration clinical research.